How Does Atropine Affect Eye Pressure?

Systemic atropine may increase intraocular pressure (IOP) by more than 6 mmHg in about 8% of normal adults [1.3.2]. This article explains the mechanisms behind this effect, detailing how does atropine affect eye pressure, particularly in individuals with different types of glaucoma.

Quick Summary

Atropine affects eye pressure primarily by dilating the pupil (mydriasis), which can physically narrow the eye's drainage angle and impede aqueous humor outflow, leading to a potential increase in IOP.

Key Points

• Primary Mechanism: Atropine increases eye pressure mainly by dilating the pupil (mydriasis), which can obstruct the eye's aqueous humor drainage system [1.2.1].

• Angle-Closure Glaucoma Risk: Atropine is contraindicated in individuals with narrow angles as it can precipitate an acute angle-closure attack, a medical emergency [1.4.6, 1.4.4].

• Open-Angle Glaucoma Impact: In patients with open-angle glaucoma, atropine can still cause significant IOP spikes in up to 32% of cases by impeding an already compromised outflow [1.2.1, 1.6.6].

• Dual Action: While atropine can impede the primary (trabecular) outflow pathway, it may slightly increase the secondary (uveoscleral) outflow pathway by relaxing the ciliary muscle [1.3.4].

• Myopia Control: Low-dose atropine for myopia control in children generally does not cause significant IOP changes, but routine monitoring is still recommended due to individual variability [1.7.1, 1.7.3].

• Predictive Factor: The degree of IOP rise after pupillary dilation in open-angle glaucoma patients can be an indicator of future disease progression [1.6.4].

• Clinical Precaution: Pre-screening with gonioscopy to assess the eye's drainage angle and post-dilation IOP checks are critical safety measures for at-risk patients [1.2.1, 1.8.1].

Understanding Atropine and Its Ocular Effects

Atropine is a potent anticholinergic medication, specifically a non-selective muscarinic receptor antagonist, derived from the belladonna plant [1.4.1, 1.7.4, 1.2.5]. In ophthalmology, it is used for its powerful cycloplegic and mydriatic properties [1.5.2, 1.2.5]. Cycloplegia is the paralysis of the ciliary muscle, which inhibits the eye's ability to accommodate or focus on near objects [1.2.1, 1.3.2]. Mydriasis is the dilation of the pupil [1.2.1]. These effects are crucial for certain diagnostic eye exams, treating conditions like amblyopia ('lazy eye'), and more recently, in low concentrations for managing myopia (nearsightedness) progression in children [1.7.4, 1.9.1]. However, these same mechanisms can have a significant and sometimes dangerous impact on intraocular pressure (IOP), the fluid pressure inside the eye.

The Core Mechanism: How Does Atropine Affect Eye Pressure?

The effect of atropine on eye pressure is complex and multifaceted. The primary concern revolves around its mydriatic effect. By dilating the pupil, atropine can cause the peripheral iris to bunch up and narrow the anterior chamber angle—the drainage system where the eye's internal fluid, the aqueous humor, exits [1.2.1].

There are two main proposed mechanisms for IOP elevation after dilation [1.2.1, 1.6.2]:

1. Reduced Trabecular Outflow: By blocking the parasympathetic innervation, atropine paralyzes the ciliary muscle [1.3.2]. This may reduce the natural traction on the trabecular meshwork, a key part of the eye's drainage system, impeding the outflow of aqueous humor and consequently increasing IOP [1.2.1].
2. Pigment Dispersion: As the pupil dilates, friction between the iris and the lens can cause pigment granules to be released into the anterior chamber. These pigments can clog the trabecular meshwork, obstructing fluid drainage and raising IOP [1.2.1].

Interestingly, atropine can also have a counteracting effect. The relaxation of the ciliary muscle can increase the uveoscleral outflow, an alternative drainage pathway for the aqueous humor [1.3.4, 1.3.3]. The ultimate change in IOP is a balance between these competing actions—the decreased trabecular outflow and the increased uveoscleral outflow [1.2.1]. In healthy eyes, this change is often negligible, but in susceptible individuals, the balance can be tipped towards a significant pressure spike [1.5.1].

Atropine's Impact on Different Types of Glaucoma

The risk associated with atropine is not uniform across all individuals and is significantly higher for those with specific types of glaucoma.

Angle-Closure Glaucoma

For patients with narrow angles or those predisposed to primary angle-closure glaucoma, atropine is a significant risk factor and often contraindicated [1.4.6, 1.3.2]. In these individuals, the drainage angle is already anatomically constricted. Pharmacological pupil dilation from atropine can cause the iris to bunch up and physically block the trabecular meshwork, leading to a sudden and sharp increase in IOP known as an acute angle-closure attack [1.4.4]. This is a medical emergency that can lead to rapid vision loss [1.4.3]. Predisposing factors include a shallow anterior chamber and hyperopia (farsightedness) [1.3.2, 1.6.3].

Open-Angle Glaucoma

In primary open-angle glaucoma (POAG), the drainage angle is open, but the trabecular meshwork does not function correctly. While the risk is less dramatic than in angle-closure, atropine can still cause a significant IOP spike in 16-32% of patients with POAG [1.2.1]. The mechanism is thought to be a further reduction in the already compromised outflow facility [1.2.1]. Studies have shown that the magnitude of IOP increase after dilation can be a predictor for future glaucoma progression, making routine monitoring crucial [1.6.4]. Systemically administered atropine is considered safe for most POAG patients, but caution and monitoring are advised [1.5.1].

Comparison Table: Atropine vs. Other Common Cycloplegics

Feature	Atropine	Cyclopentolate	Tropicamide
Primary Use	Myopia control, amblyopia, uveitis	Cycloplegic refraction, uveitis	Pupillary dilation for fundus exam [1.6.1]
Onset of Action	Slow	Rapid (30-60 mins) [1.8.1]	Fast (20-40 mins) [1.6.2]
Duration of Action	Very long (7-14 days)	Moderate (24 hours)	Short (4-8 hours) [1.6.2]
Risk of IOP Spike	Highest, especially in narrow angles [1.2.1, 1.4.2]	Moderate; known to cause IOP elevation [1.8.1]	Lower, but still can increase IOP [1.8.5]
Systemic Side Effects	Most likely due to long duration [1.8.3]	Possible, but less than atropine	Least likely of the three

Clinical Management and Monitoring

Given the potential for significant IOP elevation, careful patient screening is essential before administering atropine or other dilating agents. This includes a history review for glaucoma and gonioscopy to assess the anterior chamber angle [1.8.1]. In patients with known glaucoma or those identified as high-risk, IOP should be rechecked after dilation [1.2.1]. If a significant pressure spike occurs, it is managed by stopping the offending drug and administering IOP-lowering medications that reduce aqueous humor production [1.9.5, 1.9.3]. Pilocarpine, a miotic that constricts the pupil, is contraindicated as it can worsen the condition [1.9.3]. For children on long-term low-dose atropine for myopia control, routine IOP monitoring is recommended due to significant individual variations in pressure response [1.7.1, 1.9.4].

Conclusion

Atropine's effect on eye pressure is a double-edged sword. Its ability to dilate the pupil and paralyze the ciliary muscle is therapeutically valuable, but it carries a distinct risk of increasing intraocular pressure. This risk is most acute in individuals with undiagnosed or known narrow-angle glaucoma, where it can precipitate a sight-threatening emergency. In patients with open-angle glaucoma, it can also cause significant pressure spikes that may accelerate disease progression. Therefore, a thorough understanding of a patient's ocular anatomy and glaucoma risk, combined with careful monitoring, is paramount whenever atropine or any mydriatic agent is used.

---

For more information on the effects of pupillary dilation, you may find this article from the National Institutes of Health informative: https://pmc.ncbi.nlm.nih.gov/articles/PMC3499138/

Frequently Asked Questions

Can atropine cause permanent glaucoma?

Atropine itself does not cause chronic glaucoma, but it can trigger an acute angle-closure glaucoma attack in predisposed individuals, which can lead to permanent vision loss if not treated immediately [1.4.3]. In open-angle glaucoma, it can cause pressure spikes that may contribute to the progression of existing optic nerve damage [1.6.4].

Why is atropine contraindicated in narrow-angle glaucoma?

Atropine is contraindicated because its pupil-dilating effect can cause the iris to block the eye's narrow drainage angle, leading to a rapid and dangerous increase in intraocular pressure (acute angle-closure glaucoma) [1.4.6, 1.4.4].

Does atropine always increase eye pressure?

No, the effect varies. While atropine can increase eye pressure, especially in those with glaucoma or narrow angles, some individuals may experience no change or even a slight decrease [1.2.1]. The net effect depends on the balance between reduced trabecular outflow and increased uveoscleral outflow [1.3.3, 1.2.1].

How long does atropine affect the eye?

Atropine is a very long-acting drug. Its effects on pupil dilation and focusing can last for 7 to 14 days after a single application.

Is it safe to use low-dose atropine for myopia control in children?

Most studies show that long-term use of low-dose atropine (e.g., 0.01% - 0.05%) for myopia control does not cause a statistically significant increase in intraocular pressure in most children [1.7.1, 1.7.3]. However, because of individual variations, regular IOP monitoring is still recommended [1.9.4].

What should be done if eye pressure increases after atropine use?

If a significant rise in intraocular pressure occurs, the use of atropine should be stopped immediately. A doctor would then prescribe IOP-lowering medications, typically those that reduce the production of aqueous fluid in the eye [1.9.5, 1.9.3].

Does systemic atropine (e.g., given by injection) affect eye pressure?

Yes, systemic atropine can also affect eye pressure. Studies have shown it can cause an IOP elevation of more than 6 mm Hg in a small percentage of normal adults and can precipitate angle-closure glaucoma in those who are predisposed [1.3.2, 1.4.3].